Probucol prevents atrial ion channel remodeling in an alloxaninduced diabetes rabbit model

Oncotarget

Volumn 7, Issue 51, 2016, Pages 83850-83858

  Fu, Huaying ^a   Li, Guangping ^a   Liu, Changle ^a   Li, Jian ^a   Cheng, Lijun ^a   Yang, Wansong ^a   Tse, Gary ^b   Zhao, Jichao ^c   Liu, Tong ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alloxan induced diabetes; Atrial fibrillation; Atrial ionic remodeling; Calcium current; Diabetes mellitus; Pathology Section

Indexed keywords

CATALASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MYELOPEROXIDASE; NITROGEN; PROBUCOL; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UREA; ALLOXAN; ANTIARRHYTHMIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; ION CHANNEL;

ACTION POTENTIAL; ALLOXAN-INDUCED DIABETES MELLITUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; ATRIAL ION CHANNEL REMODELING; CARDIAC MUSCLE CELL; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; ION CURRENT; NONHUMAN; OXIDATIVE STRESS; RABBIT; VOLTAGE CLAMP TECHNIQUE; ANIMAL; ATRIAL FIBRILLATION; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HEART ATRIUM; HEART ATRIUM REMODELING; LEPORIDAE; METABOLISM; PATHOPHYSIOLOGY; TIME FACTOR;

ACTION POTENTIALS; ALLOXAN; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; ATRIAL FIBRILLATION; ATRIAL REMODELING; BIOMARKERS; DIABETES MELLITUS, EXPERIMENTAL; HEART ATRIA; ION CHANNELS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROBUCOL; RABBITS; TIME FACTORS;

EID: 85007452370     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13339     Document Type: Article

References (48)

1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, and Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129:837-847.
2. Movahed MR, Hashemzadeh M, and Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005; 105:315-318
3. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, and Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117:1255-1260.
4. Nichols GA, Reinier K, and Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care. 2009; 32:1851-1856.
5. Zhang Q, Liu T, Ng CY, and Li G. Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies. Cardiovasc Ther. 2014; 32:233-241.
6. Goette A, Honeycutt C, and Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation.1996; 94:2968-2974.
7. Liu T, Zhao H, Li J, Korantzopoulos P, and Li G. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiovasc Ther. 2014; 32:178-183.
8. Liu C, Fu H, Li J, Yang W, Cheng L, Liu T, and Li G. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Derg.2012; 12:543-550.
9. Fu H, Li G, Liu C, Li J, Wang X, Cheng L, and Liu T. Probucol Prevents Atrial Remodeling by Inhibiting Oxidative Stress and TNF-a/NF-?B/TGF-ß Signal Transduction Pathway in Alloxan-induced Diabetic Rabbits. J Cardiovasc Electrophysiol. 2015, 26:211-222.
10. Sridhar A, Nishijima Y, Terentyev D, Khan M, Terentyeva R, Hamlin RL, and Nakayama T. Chronic heart failure and the substrate for atrial fibrillation. Cardiovasc Res.2009; 84:227-236.
11. Vest JA1, Wehrens XH, Reiken SR, Lehnart SE, Dobrev D, Chandra P, Danilo P, Ravens U, Rosen MR, and Marks AR. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation. 2005; 111:2025-2032.
12. Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, Liu H, and Dudley SC Jr. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol. 2008; 294:C372-379.
13. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, and Nattel S. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000; 101:2631-2638
14. Karmazínová M, and Lacinová L. Measurement of cellular excitability by whole cell patch clamp technique. Physiol Res. 2010; 59 Suppl 1: S1-7.
15. Zimmer T, Haufe V, and Blechschmidt S. Voltage-gated sodium channels in the mammalian heart. Glob Cardiol Sci Pract. 2014; 2014:449-463.
16. Xin X, Khan ZA, Chen S, and Chakrabarti S. Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelin-mediated fibronectin synthesis. Lab Invest. 2004; 84:1451-1459.
17. Khan ZA, Barbin YP, Farhangkhoee H, Beier N, Scholz W, and Chakrabarti S.Glucose-induced serum-and glucocorticoid-regulated kinase activation in oncofetal fibronectin expression. Biochem Biophys Res Commun. 2005; 329:275-280.
18. Zhou J, Yi J, Hu N, George AL Jr, and Murray KT. Activation of protein kinase A modulates trafficking of the human cardiac sodium channel in Xenopus oocytes. Circ Res. 2000; 87:33-38.
19. Shin HG, and Murray KT. Conventional protein kinase C isoforms and cross-activation of protein kinase A regulate cardiac Na+ current. FEBS Lett.2001; 495:154-158.
20. Yanagita T, Kobayashi H, Yamamoto R, Kataoka H, Yokoo H, Shiraishi S, Minami S, Koono M, and Wada A. Protein kinase C-alpha and-epsilon down-regulate cell surface sodium channels via differential mechanisms in adrenal chromaffin cells. J Neurochem. 2000; 74:1674-1684.
21. Shang LL, and Dudley SC Jr. Tandem promoters and developmentally regulated 5'-and 3'-mRNA untranslated regions of the mouse Scn5a cardiac sodium channel. J Biol Chem. 2005, 280: 933-940.
22. Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, Liu H, and Dudley SC Jr. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II.Am J Physiol Cell Physiol. 2008;294:C372-937.
23. Li T, Chen W, An F, Tian H, Zhang J, Peng J, Zhang Y, and Guo Y. Probucol attenuates inflammation and increases stability of vulnerable atherosclerotic plaques in rabbits. Tohoku J Exp Med. 2011; 225:23-34.
24. Colle D, Santos DB, Moreira EL, Hartwig JM, dos Santos AA, Zimmermann LT, Hort MA, and Farina M. Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats.PLoS One. 2013; 8:e67658.
25. Richard S, Leclercq F, Lemaire S, Piot C, and Nargeot J. Ca2+ currents in compensated hypertrophy and heart failure.Cardiovasc Res.1998;37:300-311.
26. Lai LP, Su MJ, Lin JL, Lin FY, Tsai CH, Chen YS, Huang SK, Tseng YZ, and Lien WP.Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol.1999;33:1231-1237.
27. Ohkusa T, Ueyama T, Yamada J, Yano M, Fujumura Y, Esato K, Matsuzaki M. Alterations in cardiac sarcoplasmic reticulum Ca2+ regulatory proteins in the atrial tissue of patients with chronic atrial fibrillation. Am Coll Cardiol.1999; 34:255-63.
28. Grammer JB, Zeng X, Bosch RF, and Kühlkamp V. Atrial L-type Ca2+-channel, beta-adrenorecptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation.Basic Res Cardiol. 2001; 96:82-90.
29. van der Velden HMW, van der Zee L, Wijffels MC, van Leuven C, Dorland R, Vos MA, Jongsma HJ, and Allessie MA. Atrial fibrillation in the goat induces changes in monophasic action potential and mRNA expression of ion channels involved in repolarization.J Cardiovasc Electrophysiol. 2000;11:1262-1269.
30. Grammer JB, Bosch RF, Kühlkamp V, and Seipel L. Molecular and electrophysiological evidence for "remodeling" of the L-type Ca2+ channel in persistent atrial fibrillation in humans.Z Kardiol. 2000; 89 Suppl 4:IV23-9.
31. Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, and Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation.Circ Res.1999; 85:428-436.
32. Workman AJ, Pau D, Redpath CJ, Marshall GE, Russell JA, Kane KA, Norrie J, and Rankin AC. Post-operative atrial fibrillation is influenced by beta-blocker therapy but not by pre-operative atrial cellular electrophysiology. J Cardiovasc Electrophysiol.2006; 17:1230-1238.
33. Greiser M, Lederer WJ, and Schotten U. Alterations of atrial Ca(2+) handling as cause and consequence of atrial fibrillation.Cardiovasc Res. 2011;89:722-733.
34. Tieleman RG, De Langen C, Van Gelder IC, de Kam PJ, Grandjean J, Bel KJ, Wijffels MC, Allessie MA, and Crijns HJ. Verapamil reduces tachycardia-induced electrical remodeling of the atria.Circulation. 1997; 95:1945-1953.
35. Daoud EG, Knight BP, Weiss R, Bahu M, Paladino W, Goyal R, Man KC, Strickberger SA, and Morady F. Effect of verapamil and procainamide on atrial fibrillationinduced electrical remodeling in humans. Circulation. 1997; 96:1542-1550.
36. Ravens U, and Himmel HM. Drugs preventing Na+ and Ca2+ overload. Pharmacol Res.1999; 39:167-174.
37. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002; 415:219-226.
38. Wakili R, Voigt N, Kääb S, Dobrev D, and Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011; 121:2955-2968.
39. Tse G. Mechanisms of Cardiac Arrhythmias. J Arrhythm. 2015; 32(2):75-81.
40. Tse G, Tse V and Yeo JM. Ventricular anti-arrhythmic effects of heptanol in hypokalaemic, Langendorff-perfused mouse hearts. Biomed Rep. 2016; 4:313-324.
41. Tse G, Tse V, Yeo JM, and Sun B. Atrial anti-arrhythmic effects of heptanol in Langendorff-perfused mouse hearts. PLoS One. 2016; 11(2):e0148858.
42. Tse G, Wong ST, Tse V, and Yeo JM. Restitution analysis of alternans using dynamic pacing and its comparison with S1S2 restitution in heptanol-treated, hypokalaemic Langendorff-perfused mouse hearts. Biomed Rep. 2016; 4:673-680.
43. Tse G, Sun B, Wong ST, Tse V, and Yeo JM. Ventricular anti-arrhythmic effects of hypercalcaemia treatment in hyperkalaemic, Langendorff-perfused mouse hearts. Biomed Rep. 2016; 5:301-310.
44. Tse G, Yeo JM, Tse V, Kwan SK, and Sun B. Gap junction inhibition by heptanol increases ventricular arrhythmogenicity by decreasing conduction velocity without affecting repolarization properties or myocardial refractoriness in Langendorff-perfused mouse hearts. Mol Med Rep. 2016; 14:4069-4074.
45. Tse G, Hothi SS, Grace AA, and Huang CL. Ventricular arrhythmogenesis following slowed conduction in heptanoltreated, Langendorff-perfused mouse hearts. J Physiol Sci. 2012; 62:79-92.
46. Song Y, Shryock JC, and Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol. 2008; 294:H2031-2039.
47. Barrington PL. Interactions of H2O2, EGTA and patch pipette recording methods in feline ventricular myocytes. J Mol Cell Cardiol. 1994; 26:557-568.
48. Qu Y, Fang M, Gao B, Amagasu S, Crumb WJ, and Vargas HM. Oxytocin does not directly alter cardiac repolarization in rabbit or human cardiac myocytes. Pharmacol Res Perspect.2015; 3:e00102.